M&As, Strong Earnings, and Share Repurchase Programs Support Optimism for Healthcare - Research Report on Perrigo, Intuitive Surgical, Biogen Idec, Celgene, and Lilly

NEW YORK, August 1, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Perrigo Company (NYSE: PRGO), Intuitive Surgical, Inc. (NASDAQ: ISRG), Biogen Idec Inc. (NASDAQ: BIIB), Celgene Corporation (NASDAQ: CELG), and Eli Lilly and Company (NYSE: LLY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Perrigo Company Research Report

On July 29, 2013, Perrigo Company (Perrigo) announced that it has entered into an agreement with Elan Corporation plc (Elan) for the acquisition of Elan for $8.6 billion. Perrigo reported that as a result of this transaction, Elan shareholders will receive $6.25 in cash and approximately 0.08 shares of New Perrigo (the new company to be formed after combining Perrigo and Elan) for each Elan share. Joseph C. Papa, Chairman and CEO of Perrigo, stated, "We believe this transaction is compelling for Elan shareholders and fully takes into account the value of Elan's assets, including a large cash balance and a double-digit royalty claim on Tysabri, a blockbuster product that generated revenues of $1.6 billion last year and has been growing at a compound annual growth rate of 19%. We believe the combination of Perrigo and Elan will create an industry-leading global healthcare company with the balance sheet liquidity and operational structure to accelerate our growth and capitalize on international market opportunities." The Full Research Report on Perrigo Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/4168_PRGO]

Intuitive Surgical, Inc. Research Report

On July 29, 2013, Intuitive Surgical, Inc. (Intuitive Surgical) announced that its Board of Directors has approved an additional repurchase of $779 million of the Company's common stock. Intuitive Surgical reported that post this approval the total amount available for repurchase stands nearly at $1.5 billion, including $721 million remaining from its previous authorizations. Dr. Gary S. Guthart, President and CEO of Intuitive Surgical, commented, "Our program to repurchase $1.5 billion in Intuitive Surgical stock, including $500 million on an accelerated basis, demonstrates our commitment to our shareholders as well as our confidence in the da Vinci surgical system and the benefits it brings to patients." The Full Research Report on Intuitive Surgical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/5f98_ISRG]

Biogen Idec Inc. Research Report

On July 25, 2013, Biogen Idec Inc. (Biogen Idec) released its Q2 2013 financial results. Revenues were up 21.3% YoY to $1.7 billion. Income from operations was up 31% YoY to $662.5 million. Net income attributable to the Company was up 26.8% YoY to $490.7 million. Diluted EPS was up 28% YoY to $2.06. George A. Scangos, Ph.D., CEO of Biogen Idec, commented, "With a strong start for TECFIDERA in the U.S., as well as approvals in Canada and Australia, we expanded our leadership position in the treatment of multiple sclerosis. With three regulatory filings completed, three potential launches in 2014, and data readouts expected in 2015 and 2016, we have entered a new era of growth for the benefit of patients, clinicians and our shareholders." Biogen Idec raised its full-year 2013 guidance, expecting revenue growth to be between 22% YoY to 23% YoY and GAAP diluted EPS to be in the range of $7.28 to $7.53. The Full Research Report on Biogen Idec Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/b95b_BIIB]

Celgene Corporation Research Report

On July 25, 2013, Celgene Corporation (Celgene) released its Q2 2013 financial results. Revenues were up 17% YoY to $1.6 billion and net product sales were up 17% YoY to approximately $1.6 billion. Operating income was up 27.7% YoY to $563.7 million. Net income was up 30.1% YoY to $478.1 million. Diluted EPS was up 35.4% YoY to $1.11, whereas adjusted diluted EPS was up 24.6% YoY to $1.52. Bob Hugin, Chairman and CEO of Celgene, said, "The positive outcome of the MM-020 trial along with other clinical and regulatory milestones met in the quarter represent significant advances for patients worldwide and support our commitment to our long-term growth outlook." Celgene also raised its full-year 2013 guidance for adjusted diluted EPS to be in the range of $5.80 to $5.90, and net product sales to be in the range of $4.2 billion to $4.3 billion. The Full Research Report on Celgene Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/7f47_CELG]

Eli Lilly and Company Research Report

On July 24, 2013, Eli Lilly and Company (Lilly) released its Q2 2013 financial results. Revenues were up 5.9% YoY to $5.9 billion. Non-GAAP net income was up 35.9% YoY to approximately $1.3 billion. Non-GAAP EPS was up 39.8% YoY to $1.16. John C. Lechleiter, Ph.D., Chairman, President, and CEO of Lilly, stated, "In the second quarter, Lilly delivered solid financial results, highlighted by good revenue growth and strict cost containment efforts that led to robust earnings growth. Continued operating and financial discipline, along with a maturing pipeline of potential new medicines, gives me great confidence in the company's ability to meet the challenges we face from upcoming patent expirations and to resume growth after 2014." Lilly also raised its full-year 2013 guidance for non-GAAP EPS to be in the range of $4.05 to $4.15. The Full Research Report on Eli Lilly and Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/977d_LLY]

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Analysts' Corner